Aethlon Medical (STU:EJU) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:EJU Aethlon Medical Inc STU:EJU
19 GF Score
Price €212.00
! 1 Warning Sign
View Full Analysis

What is Aethlon Medical LT-Debt-to-Total-Asset?

Aethlon Medical STU:EJU 19 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates STU:EJU with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aethlon Medical's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Aethlon Medical's long-term debt to total assets ratio declined from Mar. 2025 (0.05) to Mar. 2026 (0.00). It may suggest that Aethlon Medical is progressively becoming less dependent on debt to grow their business.

Aethlon Medical  (STU:EJU) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aethlon Medical LT-Debt-to-Total-Asset Related Terms

Aethlon Medical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Aethlon Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aethlon Medical LT-Debt-to-Total-Asset Chart

Aethlon Medical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.05 0.08 0.05 0.00

Aethlon Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.02 0.01 0.00
STU:EJU
19GF Score
Aethlon Medical Inc STU:EJU
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aethlon Medical LT-Debt-to-Total-Asset Calculation

Aethlon Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=0/5.478
=

Aethlon Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0/5.478
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Aethlon Medical (STU:EJU) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aethlon Medical and its competitors.
Is Aethlon Medical's LT-Debt-to-Total-Asset too high?
Aethlon Medical's current LT-Debt-to-Total-Asset is 0.00. Overall, Aethlon Medical has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's LT-Debt-to-Total-Asset compare to NUMD and AMIX?
Aethlon Medical's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aethlon Medical and its competitors. Aethlon Medical's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (STU:EJU) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Aethlon Medical's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Aethlon Medical (STU:EJU), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aethlon Medical Business Description

Other Exchanges AEMD:USA
Address 11555 Sorrento Valley Road, Suite 203, San Diego, CA, USA, 92121
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
19GF Score

Get the complete analysis for STU:EJU

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€212.00
Price